You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than serovars of the genus Leptospira In the US there is increasing awareness of the importance of leptospirosis as the cause of disease among inner city populations military personnel and individuals ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    DESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of PAR Pepducins as a Novel Antithrombotic Treatment

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Coronary artery disease remains the leading cause of death in the United States Platelets play an important role in the pathogenesis of acute coronary syndrome ACS as platelet activation aggregation and secretion are key components of arterial thrombus formation Despite dual anti platelet therapy for ACS and percutaneous coronary interventions PCI many patients sustain a high incidence u ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. A novel approach to treat non alcoholic steatohepatitis NASH

    SBC: Mitotherapeutix LLC            Topic: 300

    Abstract The Specific Aim of this Phase I STTR proposal is to test the feasibility of treating non alcohol steatohepatitis NASH by increasing mitochondrial metabolism which is the main pathway for lipid catabolism in the liver NASH is a stage of non alcohol fatty liver disease NAFLD that has progressed to a pathological state NASH can lead to cirrhosis leading to liver failure or hepatocel ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. HLS Cyclic CAR peptide a targeted therapy for pulmonary hypertension

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NHLBI

    PUBLIC ABSTRACT This project in response to announcement HLS describes a development program for CARSKNKDC CAR a synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapies for the treatment of pulmonary hypertension PH PH is a disorder of elevated pulmonary vascular resistance characterized by ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Development Characterization and Commercialization of a Viably Frozen Patient Inclusive Hepatocellular Carcinoma Tumor Bank

    SBC: Woodland Pharmaceuticals LLC            Topic: 103

    Abstract Hepatocellular carcinoma HCC is a disease of growing incidence globally including in the US by per year With the recent success of anti viral therapies the etiology of HCC in the American population is projected to shift from viral HBV HCV hepatitis to primarily fatty liver disease in the near future Currently only one effective systemic therapy has been developed for HCC ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. UV emitting nanoparticles as novel radiation sensitizers targeting hypoxic cells

    SBC: Radiation Monitoring Devices, Inc.            Topic: 102

    Project Summary Abstract Radiation therapy is one of the primary therapeutic techniques for treating cancer Nearly two thirds of all cancer patients will receive radiation therapy during their illness with an average of radiation treatment episodes Although largely effective radiation therapy like other forms of cancer treatment has difficulty killing hypoxic regions within solid tumors ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government